Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avidity Biosciences, Inc. - Common Stock (NQ:RNA)

72.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 72.14
Bid (Size) 72.01 (800)
Ask (Size) 72.49 (100)
Prev. Close 72.14
Today's Range 72.14 - 72.14
52wk Range 21.51 - 72.61
Shares Outstanding 54,462,518
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance

Performance

YTD
+131.4%
+131.4%
1 Month
+1.3%
+1.3%
3 Month
+70.5%
+70.5%
6 Month
+141.5%
+141.5%
1 Year
+128.0%
+128.0%

More News

Read More
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts ↗
Via Benzinga
News headline image
Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Looking Into Avidity Biosciences Inc's Recent Short Interest ↗
Via Benzinga
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Essential Utilities, Inc. (NYSE – WTRG), Cadence Bank (NYSE – CADE), Avidity Biosciences, Inc. (Nasdaq – RNA), Plymouth Industrial REIT, Inc. (NYSE – PLYM)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) ↗
Via The Motley Fool
News headline image
Unusual volume stocks in Thursday's session ↗
Via Chartmill
News headline image
$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
Via Benzinga
News headline image
Novartis Maintains Outlook Even As Generics Bite Into Profits ↗
Via Benzinga
News headline image
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours ↗
Via Benzinga
News headline image
Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Wall Street Soars as Qualcomm Ignites the AI Race ↗
Via Chartmill
Topics Artificial Intelligence Stocks
News headline image
Why Avidity Biosciences Stock Blasted 42% Higher Today ↗
Via The Motley Fool
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill

Frequently Asked Questions

Is Avidity Biosciences, Inc. - Common Stock publicly traded?
Yes, Avidity Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Avidity Biosciences, Inc. - Common Stock trade on?
Avidity Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Avidity Biosciences, Inc. - Common Stock?
The ticker symbol for Avidity Biosciences, Inc. - Common Stock is RNA on the Nasdaq Stock Market
What is the current price of Avidity Biosciences, Inc. - Common Stock?
The current price of Avidity Biosciences, Inc. - Common Stock is 72.14
When was Avidity Biosciences, Inc. - Common Stock last traded?
The last trade of Avidity Biosciences, Inc. - Common Stock was at 12/23/25 04:00 PM ET
What is the market capitalization of Avidity Biosciences, Inc. - Common Stock?
The market capitalization of Avidity Biosciences, Inc. - Common Stock is 3.93B
How many shares of Avidity Biosciences, Inc. - Common Stock are outstanding?
Avidity Biosciences, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.